Cyxone in media
BioStock article: Cyxone’s CEO gives a status update
BioStock published an article on 5 March 2024 about Cyxone, which can be read in full below. Cyxone recently reached a milestone in its rheumatoid arthritis project, rabeximod, when succeeding in identifying the molecule’s target protein. This means that...
Read MoreBioStock article: Cyxone identifies target protein for rabeximod
BioStock published an article on 17 January 2024 about Cyxone, which can be read in full below. Cyxone has put intense focus on the development of lead candidate rabeximod – an immunomodulatory treatment for rheumatoid arthritis. The company has...
Read MoreBioStock article: Cyxone’s CEO comments on the US patent notice
BioStock published an article on 6 April 2023 about Cyxone, which can be read in full below. Biotech company Cyxone develops new therapies for the treatment of autoimmune diseases, such as rheumatoid arthritis with the phase IIb candidate Rabeximod....
Read MoreBioStock article: Cyxone reports Q3 and presents T20K
BioStock published an article on 3 November 2022 about Cyxone, which can be read in full below. Malmö-based Cyxone recently published its report for the third quarter, which testifies that the company is focusing on the phase IIb study...
Read MoreBioStock article: October 12 – World Arthritis Day
BioStock published an article on 12 October 2022 about Cyxone, which can be read in full below. October 12 is World Arthritis Day, which every year draws attention to people living with arthritic diseases. This term refers to a...
Read MoreBioStock article: Erika Samuelsson new CDO at Cyxone
BioStock published an article on 22 September 2022 about Cyxone, which can be read in full below. At the beginning of the autumn, First North-listed Cyxone announced the recruitment of Erika Samuelsson as the new Chief Development Officer with...
Read MoreBioStock article: Cyxone looks forward to study start
BioStock published an article on 31 August 2022 about Cyxone, which can be read in full below. Biopharmaceutical company Cyxone is fully focused on the upcoming phase IIb study with the candidate Rabeximod in rheumatoid arthritis. In the company’s...
Read MoreBioStock article: Cyxone comments on scientific T20K article
BioStock published an article on 19 August 2022 about Cyxone, which can be read in full below. This week, the scientific journal Biomedicine & Pharmacotherapy published an article regarding T20K, Cyxone’s drug candidate in multiple sclerosis. Behind the article...
Read MoreBioStock article: New IR force at Cyxone
BioStock published an article on 7 July 2022 about Cyxone, which can be read in full below. In June, biotech Cyxone announced a change of management – Carl-Magnus Högerkorp stepped up from his role as Chief Operating Officer to...
Read MoreBioStock article: New management in Cyxone
BioStock published an article on 22 June 2022 about Cyxone, which can be read in full below. The board of Malmö-based company Cyxone recently announced a change in management. Carl-Magnus Högerkorp, Chief Operating Officer, steps in as acting CEO...
Read More